Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock
Key stats
- Market cap
- $2.17B
- Price / Earnings ratio
- 7.0x
- EPS (TTM)
- $2.36
- Volume
- Loading
- 52-week high
- $19.25
- 52-week low
- $13.52
Source: third-party data provider, as of November 13, 2026
Compare with AUPH
Recent news

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
AUPH

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
AUPH

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
AUPH

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
AUPH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 45.29
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- 0.06
- MACD histogram
- -0.09
- SMA 50
- $16.49
- Price below SMA 50
- EMA 50
- $16.47
- Price below EMA 50
- SMA 200
- $15.72
- Price above SMA 200
- EMA 200
- $15.89
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
AUPH

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
AUPH

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
AUPH

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
AUPH

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
AUPH

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH

AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH Stock Rallies 6% After-Hours — Here’s Why
AUPH

Aurinia Settles Patent Litigation with Teva
Aurinia Settles Patent Litigation with Teva
AUPH

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
AUPH

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
AUPH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Aurinia Pharmaceuticals Inc Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin C. Tang | Chairman & CEO | 1967 |
| Mr. Michael S. Hearne CPA | Chief Financial Officer | 1963 |
| Mr. Ryan Cole | Chief Operating Officer | 1987 |
| Mr. Stephen P. Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 1982 |
| Mr. Peter S. Greenleaf M.B.A. | Consultant | 1970 |
| Mr. Thomas Wei | Chief Scientific Officer | 1976 |
| Mr. Stewart M. Kroll | Chief Development Officer | 1959 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 45.29
- MACD 12/26/9
- -0.03
- EMA 9 of MACD
- 0.06
- MACD histogram
- -0.09
- SMA 50
- $16.49
- Price below SMA 50
- EMA 50
- $16.47
- Price below EMA 50
- SMA 200
- $15.72
- Price above SMA 200
- EMA 200
- $15.89
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $18.00
- Average
- $18.00
- High
- $18.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -30.3 | +28.6 | ||||||||||
| 2022 | -25.9 | -30.3 | +3.1 | -18.3 | +3.6 | -9.3 | -28.2 | -9.6 | +3.2 | +9.9 | -36.0 | -14.8 |
| 2023 | +52.4 | -1.9 | +21.9 | +9.0 | -20.0 | +6.1 | +15.9 | -13.2 | -17.9 | -1.3 | +21.2 | -0.8 |
| 2024 | -13.7 | -26.0 | -13.3 | -5.7 | +4.2 | +6.5 | +7.1 | +21.4 | +9.7 | -0.7 | +21.0 | -1.3 |
| 2025 | -9.4 | +1.8 | +0.8 | +2.4 | -4.4 | +6.4 | +23.7 | +14.3 | -5.4 | +15.5 | +22.4 | -1.4 |
| 2026 | -5.3 | -6.9 | +4.3 | -0.5 | -0.1 | +10.8 | -5.8 | +10.6 | +0.9 | +4.4 | +0.4 |



